449 related articles for article (PubMed ID: 37888583)
41. Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
Zhang Q; Lou Y; Bai XL; Liang TB
World J Gastroenterol; 2018 Aug; 24(31):3500-3512. PubMed ID: 30131656
[TBL] [Abstract][Full Text] [Related]
42. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target.
Alvisi G; Termanini A; Soldani C; Portale F; Carriero R; Pilipow K; Costa G; Polidoro M; Franceschini B; Malenica I; Puccio S; Lise V; Galletti G; Zanon V; Colombo FS; De Simone G; Tufano M; Aghemo A; Di Tommaso L; Peano C; Cibella J; Iannacone M; Roychoudhuri R; Manzo T; Donadon M; Torzilli G; Kunderfranco P; Di Mitri D; Lugli E; Lleo A
J Hepatol; 2022 Nov; 77(5):1359-1372. PubMed ID: 35738508
[TBL] [Abstract][Full Text] [Related]
43. Circular RNAs in cholangiocarcinoma.
Liao W; Feng Q; Liu H; Du J; Chen X; Zeng Y
Cancer Lett; 2023 Jan; 553():215980. PubMed ID: 36336149
[TBL] [Abstract][Full Text] [Related]
44. The present roles and future perspectives of Interleukin-6 in biliary tract cancer.
Zhou M; Na R; Lai S; Guo Y; Shi J; Nie J; Zhang S; Wang Y; Zheng T
Cytokine; 2023 Sep; 169():156271. PubMed ID: 37331095
[TBL] [Abstract][Full Text] [Related]
45. Heterogeneity, crosstalk, and targeting of cancer-associated fibroblasts in cholangiocarcinoma.
Cantallops Vilà P; Ravichandra A; Agirre Lizaso A; Perugorria MJ; Affò S
Hepatology; 2024 Apr; 79(4):941-958. PubMed ID: 37018128
[TBL] [Abstract][Full Text] [Related]
46. The Prognostic Role of SOCS3 and A20 in Human Cholangiocarcinoma.
Wang Y; Wan M; Zhou Q; Wang H; Wang Z; Zhong X; Zhang L; Tai S; Cui Y
PLoS One; 2015; 10(10):e0141165. PubMed ID: 26485275
[TBL] [Abstract][Full Text] [Related]
47. Identification of Four Immune Subtypes Characterized by Distinct Composition and Functions of Tumor Microenvironment in Intrahepatic Cholangiocarcinoma.
Job S; Rapoud D; Dos Santos A; Gonzalez P; Desterke C; Pascal G; Elarouci N; Ayadi M; Adam R; Azoulay D; Castaing D; Vibert E; Cherqui D; Samuel D; Sa Cuhna A; Marchio A; Pineau P; Guettier C; de Reyniès A; Faivre J
Hepatology; 2020 Sep; 72(3):965-981. PubMed ID: 31875970
[TBL] [Abstract][Full Text] [Related]
48. New and Emerging Systemic Therapeutic Options for Advanced Cholangiocarcinoma.
Massironi S; Pilla L; Elvevi A; Longarini R; Rossi RE; Bidoli P; Invernizzi P
Cells; 2020 Mar; 9(3):. PubMed ID: 32168869
[TBL] [Abstract][Full Text] [Related]
49. Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma.
Wang N; Wang L; Huang A; Han J; Cao T; Mei X; Yao J; Xiao Y; Ma H
Front Immunol; 2023; 14():1273962. PubMed ID: 38162668
[TBL] [Abstract][Full Text] [Related]
50. Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.
Wang J; Ilyas S
Expert Opin Investig Drugs; 2021 Apr; 30(4):429-438. PubMed ID: 33322977
[No Abstract] [Full Text] [Related]
51. Italian Clinical Practice Guidelines on Cholangiocarcinoma - Part II: Treatment.
Cholangiocarcinoma Working Group
Dig Liver Dis; 2020 Dec; 52(12):1430-1442. PubMed ID: 32952071
[TBL] [Abstract][Full Text] [Related]
52. Conjugated bile acids promote cholangiocarcinoma cell invasive growth through activation of sphingosine 1-phosphate receptor 2.
Liu R; Zhao R; Zhou X; Liang X; Campbell DJ; Zhang X; Zhang L; Shi R; Wang G; Pandak WM; Sirica AE; Hylemon PB; Zhou H
Hepatology; 2014 Sep; 60(3):908-18. PubMed ID: 24700501
[TBL] [Abstract][Full Text] [Related]
53. The immune microenvironment features and response to immunotherapy in EBV-associated lymphoepithelioma-like cholangiocarcinoma.
Chiang NJ; Hou YC; Tan KT; Tsai HW; Lin YJ; Yeh YC; Chen LT; Hou YF; Chen MH; Shan YS
Hepatol Int; 2022 Oct; 16(5):1137-1149. PubMed ID: 35780451
[TBL] [Abstract][Full Text] [Related]
54. The state of therapy modalities in clinic for biliary tract cancer.
Chen W; Hu Z; Song J; Wu Y; Zhang B; Zhang L
Front Biosci (Landmark Ed); 2022 Jun; 27(6):185. PubMed ID: 35748261
[TBL] [Abstract][Full Text] [Related]
55. Multidisciplinary treatment for hilar and intrahepatic cholangiocarcinoma: A review of the general principles.
Sapisochin G; Ivanics T; Subramanian V; Doyle M; Heimbach JK; Hong JC
Int J Surg; 2020 Oct; 82S():77-81. PubMed ID: 32380231
[TBL] [Abstract][Full Text] [Related]
56. Peribiliary Glands as the Cellular Origin of Biliary Tract Cancer.
Nakagawa H; Hayata Y; Yamada T; Kawamura S; Suzuki N; Koike K
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29895797
[TBL] [Abstract][Full Text] [Related]
57. Immunotherapy for hepatobiliary cancers: Emerging targets and translational advances.
Li D; Lin S; Hong J; Ho M
Adv Cancer Res; 2022; 156():415-449. PubMed ID: 35961708
[TBL] [Abstract][Full Text] [Related]
58. Cholangiocarcinoma: Pathologic and Molecular Classification in the Era of Precision Medicine.
Gopal P; Robert ME; Zhang X
Arch Pathol Lab Med; 2024 Mar; 148(3):359-370. PubMed ID: 37327187
[TBL] [Abstract][Full Text] [Related]
59. A review of the clinical diagnosis and therapy of cholangiocarcinoma.
Yao D; Kunam VK; Li X
J Int Med Res; 2014 Feb; 42(1):3-16. PubMed ID: 24366497
[TBL] [Abstract][Full Text] [Related]
60. Cholangiocarcinoma: novel therapeutic targets.
Sato K; Glaser S; Alvaro D; Meng F; Francis H; Alpini G
Expert Opin Ther Targets; 2020 Apr; 24(4):345-357. PubMed ID: 32077341
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
